Kiniksa Pharmaceuticals, Ltd.
KNSA
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatoā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$73.62
Price-0.97%
-$0.72
1Y
Price
Market Cap
$5.610b
Mid
Price/Earnings 3y Avg5y Avg
81.8x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+11.4%
EBITDA Margin+10.4%
Net Profit Margin+19.2%
Free Cash Flow Margin+11.4%
EBITDA Margin+10.4%
Net Profit Margin+19.2%
Free Cash Flow MarginRevenue
$840.848m
+24.1%
1y CAGR+46.9%
3y CAGR+40.9%
5y CAGREarnings
$80.658m
+36.7%
1y CAGR-44.5%
3y CAGR-56.4%
5y CAGREPS
$0.98
+30.7%
1y CAGR-48.1%
3y CAGR-59.2%
5y CAGRBook Value
$654.149m
$896.110m
Assets$241.961m
Liabilities$8.897m
DebtDebt to Assets
1.0%
0.1x
Debt to EBITDAFree Cash Flow
$183.101m
+620.5%
1y CAGR+237.8%
3y CAGR+211.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company